依米妥珠单抗
化合物
依米妥珠单抗[注 1]（INN：Emibetuzumab[1]；开发代号：LY2875358）是一种人源化单克隆抗体，设计用于治疗癌症。[2]目前正处于针对非小细胞肺癌患者的II期试验中。[3]
| 单克隆抗体 | |
|---|---|
| 种类 | ? |
| 目标 | HGFR |
| 临床资料 | |
| 其他名称 | LY2875358 |
| ATC码 |
|
| 识别信息 | |
| CAS号 | 1365287-97-3 |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| 化学信息 | |
| 化学式 | C6356H9810N1694O2014S48 |
| 摩尔质量 | 143,719.12 g·mol−1 |
该药物由礼来公司开发。
注释
- ^ 有些文献资料将Emibetuzumab译作依玛妥珠单抗，而将Emactuzumab译作依米妥珠单抗
参考资料
- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111 (PDF). WHO Drug Information. 2014, 28 (2) [2024-03-12]. （原始内容存档 (PDF)于2020-08-15）.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Emibetuzumab, American Medical Association.
- ^ Camidge DR, Moran T, Demedts I, Grosch H, Di Mercurio JP, Mileham KF, et al. A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC.. [2024-03-12]. （原始内容存档于2017-03-29）.